(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 December 2009 (17.12.2009)

PCT

(10) International Publication Number
WO 2009/150469 A3

(51) International Patent Classification:
A61K 38/00 (2006.01) *A61P 5/00* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/GB2009/050665

(22) International Filing Date:
11 June 2009 (11.06.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0810785.6	12 June 2008 (12.06.2008)	GB
0810782.3	12 June 2008 (12.06.2008)	GB
0820884.5	14 November 2008 (14.11.2008)	GB
0820965.2	17 November 2008 (17.11.2008)	GB

(71) Applicant *(for all designated States except US)*: **SYNTAXIN LIMITED** [GB/GB]; Units 4-10 The Quadrant, Barton Lane, Abingdon, Oxfordshire OX14 3YS (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **JOHNSTONE, Stephen** [GB/GB]; Syntaxin Limited, Units 4-10 The Quadrant, Barton Lane, Abingdon, Oxfordshire OX14 3YS (GB). **MARKS, Philip** [GB/GB]; Syntaxin Limited, Units 4-10 The Quadrant, Barton Lane, Abingdon, Oxfordshire OX14 3YS (GB). **FOSTER, Keith** [GB/GB]; Syntaxin Limited, Units 4-10 The Quadrant, Barton Lane, Abingdon, Oxfordshire OX14 3YS (GB).

(74) Agents: **MACLEAN, Martin** et al.; 120 Holborn, London, Greater London EC1N 2SQ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
15 July 2010

(54) Title: SUPPRESSION OF NEUROENDOCRINE DISEASES

Figure 4



(57) Abstract: The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumour cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptora melanin- concentrating hormone receptor 1; a KiSS-1 receptor or a prolactin- releasing peptide receptor. When so delivered, the protease is internalised and inhibits secretion- from said tumourcell. The present invention also relates to polypeptides and nucleic acids for use in said methods.

WO 2009/150469 A3